Skip to main content
. Author manuscript; available in PMC: 2015 Jul 30.
Published in final edited form as: Pharm Res. 2015 Jan 22;32(6):2003–2014. doi: 10.1007/s11095-014-1593-y

Fig. 5.

Fig. 5

Cytotoxicity on U-87 MG cells treated by (a) doxorubicin with U-87 MG cell derived exosome, (b) doxorubicin with bEND.3 cell derived exosome, (c) paclitaxel with U-87 MG cell derived exosome, and (d) paclitaxel with bEND.3 cell derived exosome (1: 25 μM drug; 2. 100 μg/ml exosome; 3. 200 μg/ml exosome; 4. drug + 20 μg/ml exosome; 5. drug + 40 μg/ml exosome; 6. drug + 80 μg/ml exosome; 7. drug + 100 μg/ml exosome; 8. drug + 200 μg/ml exosome, * Results are significantly different, p<0.05).